Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships

Wang, Ruo; Chen, Huahong; Yan, Weitao; Zheng, Mingwen; Zhang, Tesen; Zhang, Yaohuan

doi:10.1016/j.ejmech.2020.112109

Cited by 141 publications

(69 citation statements)

References 218 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ferrocene is a useful template for the development of anticancer agents. After the development of ferrocifen, a ferrocene-phenol hybrid, under pre-clinical trial, having a different mode of action compared to cisplatin, many researchers are designing and studying ferrocene hybrids with various other moieties including heterocycles [171]. Though many research articles have been published regarding the anticancer activities of ferrocene derivatives containing pyrazolyl-moiety [172][173][174], there is only one on pyrazoline hybrids.…”

Section: Other Non-classified Pyrazoline Based Conjugatesmentioning

confidence: 99%

Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview

Matiadis

Sagnou

2020

IJMS

View full text Add to dashboard Cite

Pyrazolines are five-membered heterocycles possessing two adjacent nitrogens. They have attracted significant attention from organic and medicinal chemists due to their potent biological activities and the numerous possibilities for structural diversification. In the last decade, they have been intensively studied as targets for potential anticancer therapeutics, producing a steady yearly rise in the number of published research articles. Many pyrazoline derivatives have shown remarkable cytotoxic activities in the form of heterocyclic or non-heterocyclic based hybrids, such as with coumarins, triazoles, and steroids. The enormous amount of related literature in the last 5 years prompted us to collect all these published data from screening against cancer cell lines, or protein targets like EGFR and structure activity relationship studies. Therefore, in the present review, a comprehensive account of the compounds containing the pyrazoline nucleus will be provided. The chemical groups and the structural modifications responsible for the activity will be highlighted. Moreover, emphasis will be given on recent examples from the literature and on the work of research groups that have played a key role in the development of this field.

show abstract

Section: Other Non-classified Pyrazoline Based Conjugatesmentioning

confidence: 99%

Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview

Matiadis

Sagnou

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Complexes containing group 8 metals osmium, ruthenium and iron have shown promising anticancer properties and have been heavily studied during the past 20 + years. [81,82] Ruthenium compounds have emerged as attractive alternatives to cisplatin and as potential follow-up agents to conventional platinumbased drugs, specifically targeting metastasized solid tumors and cisplatin-resistant tumors and endowed with different mechanisms of action. [81,83] Three Ru(III) derivatives, NAMI-A and KP1019/KP1339 (Scheme 5) entered clinical trials for colorectal cancer, [84,85] while a Ru(II)-based photosensitizer (TLD-1433) has recently been fast-tracked by FDA in phase II clinical trials for treating non-muscle invasive bladder cancer (Scheme 5).…”

Section: Osmium Ruthenium and Iron Compoundsmentioning

confidence: 99%

“…Compounds containing ferrocene, a compound with a sandwich-like structure with two cyclopentadienyl rings bound to an iron (II) center, have been evaluated in TNBC cell lines. [136][137][138][139][140][141][142][143][144][145][146][147][148][149][150][151][152][153][154][155] Ferrocene and its derivatives (such as ferroquine and ferrocifen) have attractive qualities such as reversible redox properties and have displayed anticancer, antibacterial, antifungal, and antiparasitic activity. [136] Zhang and co-workers have reviewed the anticancer properties displayed by ferrocene-containing hybrids.…”

Section: Iron (Ii) Compoundsmentioning

confidence: 99%

Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer

Nayeem

Contel

2021

Chemistry A European J

View full text Add to dashboard Cite

This review focuses on studies of coordination and organometallic compounds as potential chemotherapeutics against triple negative breast cancer (TNBC) which has one of the poorest prognoses and worst survival rates from all breast cancer types. At present, chemotherapy is still the standard of care for TNBC since only one type of targeted therapy has been recently developed. References for metal-based compounds studied in TNBC cell lines will be listed, and those of metal-specific reviews, but a detailed overview will also be provided on compounds studied in vivo (mostly in mice models) and those compounds for which some preliminary mechanistic data was obtained (in TNBC cell lines and tumors) and/or for which bioactive ligands have been used. The main goal of this review is to highlight the most promising metalbased compounds with potential as chemotherapeutic agents in TNBC.

show abstract

“…Ferrocene derivatives are becoming more and more popular in medicinal molecules due to their unique chemical structures, biological activities, low toxicity, and reversible redox behavior [6]. Some compounds were found to exhibit a variety of pharmacological properties, including antibacterial [7], antimalarial [8], antifungal [9], antiviral [10], and anticancer activities [11].…”

Section: Introductionmentioning

confidence: 99%

Novel Ferrocene Derivatives Induce G0/G1 Cell Cycle Arrest and Apoptosis through the Mitochondrial Pathway in Human Hepatocellular Carcinoma

Zheng

Zeng

Tang

et al. 2021

IJMS

View full text Add to dashboard Cite

In this study, detailed information on hepatocellular carcinoma (HCC) cells (HepG-2, SMMC-7721, and HuH-7) and normal human liver cell L02 treated by ferrocene derivatives (compounds 1, 2 and 3) is provided. The cell viability assay showed that compound 1 presented the most potent and selective anti-HCC activity. Further mechanism study indicated that the proliferation inhibition effect of compound 1 was associated with the cycle arrest at the G0/G1 phase and downregulation of cyclin D1/CDK4. Moreover, compound 1 could induce apoptosis in HCC cells by loss of mitochondrial membrane potential (ΔΨm), accumulation of reactive oxygen species (ROS), decrease in Bcl-2, increase in BAX and Bad, translocation of Cytochrome c, activation of Caspase-9, -3, and cleavage of PARP. These results indicated that compound 1 would be a promising candidate against HCC through G0/G1 cell cycle arrest-related proliferation inhibition and mitochondrial pathway-dependent apoptosis.

show abstract

Ferrocene-containing hybrids as potential anticancer agents: Current developments, mechanisms of action and structure-activity relationships

Cited by 141 publications

References 218 publications

Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview

Pyrazoline Hybrids as Promising Anticancer Agents: An Up-to-Date Overview

Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer

Novel Ferrocene Derivatives Induce G0/G1 Cell Cycle Arrest and Apoptosis through the Mitochondrial Pathway in Human Hepatocellular Carcinoma

Contact Info

Product

Resources

About